
Summa Equity has acquired a majority stake in science tools business Axion BioSystems with the intent of further entering the CGT market.
Summa Equity has acquired a majority stake in science tools business Axion BioSystems with the intent of further entering the CGT market.
Following a deal struck in mid-2018, 908 Devices’ ZipChip and REBEL technology have proven instrumental in facilitating Transcenta’s efficiency and volumetric production.
Avantor’s newly unveiled J.T.Baker robotic tips is the latest in their line of automated precision plastics.
Sciex’s recently launched accurate mass instrument, the ZenoTOF 7600 system, offers novel ion fragmentation and increased sensitivity for life science research and biotherapeutic development.
The CYTRIX Microfluidic Hydrogel Kit is the first in Sphere Fluidics’ new range of 3D cell culture kits in partnership with ClexBio.
The increased number of regulatory filings for cell and gene therapies requires reevaluation of bioassay methods because of their complexity.
PPD has opened its new multipurpose clinical research laboratory in Suzhou, China, which offers bioanalytical, biomarker, and vaccine sciences services for China and the global market.
The acquisition gives PerkinElmer access to Nexcelom Bioscience’s complementary cell counting and analysis capabilities and enhances its QA/QC capabilities.
A shortage of pipette tips has been attributed to several factors, including the COVID-19 pandemic.
Dynamic light scattering presents a good analytical technique for testing protein stability.
The £500,000 (US$686,294)-investment in mass spectrometry support will accelerate biologics development and approval.
Clear understanding of what exactly the biomolecule entails is essential.
Dolomite Microfluidics and MilliporeSigma have begun a collaboration to release off-the-shelf microfluidic device kits for the fabrication of PLGA particles.
The new powerful, precise, and compact instrument can be retrofitted for point-of-care clinical testing at urgent care facilities, hospitals, or physicians’ offices.
The partners have established PathoQuest, Inc., a US subsidiary, and will construct an NGS-based testing lab at Charles River’s Wayne, PA, site.
The shift to single-use technologies is driving the need for innovation in PAT-friendly sensor technologies.
Early detection and more sensitive methods of detecting adventitious agents are becoming increasingly critical in bioprocessing.
Samsung Biologics has adopted Solentim’s cell seeding and cell metric platforms at its new R&D center in San Francisco, CA.
Mogrify’s new technology platform, EpiMOGRIFY, can predict cellular switches important for determining cell identity, cell maintenance, directed differentiation, and cell conversion.
With the presentation of research supporting the use of PTA technology, BioSkryb also launched its ResolveDNA platform for commercial use at ASHG 2020, held virtually on Oct. 27–30, 2020.
Following a recent expansion at its Cambridge, MA, facility, the company now houses a new suite of cellular analysis platforms that enhance its exploratory capabilities into oncology, neuroscience, and rare diseases.
The new personal capillary electrophoresis system, Spectrum Compact CE, performs Sanger sequencing and fragment analysis.
The company’s new CytoML Experiment Suite fully automates each stage of the flow cytometry data lifecycle, allowing for clearer data visualization and analysis.
The increased use of single-use bags in biologic manufacturing poses the risk of pinholes and other defects that cannot currently be tested for.
Current and newer biologic modalities pose increasingly complex challenges to the detection and characterization of protein aggregates.